Regeneron to Begin Human Studies of Novel SARS-CoV-2 Antibody

(Tarrytown, NY, USA) is rapidly advancing its experimental antibody treatment for COVID-19 and plans to conduct the drug’s clinical studies in humans for the first time in June 2020.

Regeneron is advancing REGN-COV2, a novel investigational antibody "cocktail" treatment designed to prevent and treat the SARS-CoV-2 virus. In April, Regeneron moved its leading neutralizing antibodies into pre-clinical and clinical-scale cell production lines and plans to begin clinical studies in June 2020. The company is working to rapidly scale-up manufacturing, with a goal to have hundreds of thousands of preventative doses available by the end of August 2020.
In order to enable its US manufacturing site to produce large-scale quantities of REGN-COV2, the company is working with the FDA to accelerate licensing of additional commercial products manufactured at its Ireland facility.

"Over 30 years, the Regeneron team has built a science and technology engine uniquely suited to address the COVID-19 pandemic and we are applying our signature passion, innovation, and drive to advance solutions. Our novel antibody cocktail, REGN-COV2, which is specifically-designed for both prevention and treatment, is expected to begin human studies in June and we are working in parallel to have large-scale quantities available by late summer," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.

Related Links:
Regeneron Pharmaceuticals, Inc.